Screener
Oruka Therapeutics, Inc. ORKA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Oruka Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
FAQ
- What is Oruka Therapeutics, Inc.'s debt-to-equity?
- Oruka Therapeutics, Inc. (ORKA) reported debt-to-equity of 0× in Q1 2026.
- How has Oruka Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Oruka Therapeutics, Inc.'s debt-to-equity increased by 42.3% year-over-year, from 0× to 0×.
- What is the long-term trend for Oruka Therapeutics, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s debt-to-equity has grown at a -15.8% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Oruka Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude